|
Volume 272, Number 52, Issue of December 26, 1997
pp. 32847-32856
1-Adrenergic Stimulation Potentiates the
Thermogenic Action of 3-Adrenoreceptor-generated cAMP in
Brown Fat Cells*
(Received for publication, July 18, 1997, and in revised form, September 10, 1997)
Jin
Zhao
,
Barbara
Cannon
and
Jan
Nedergaard
From the Wenner-Gren Institute, the Arrhenius Laboratories F3,
Stockholm University, S-106 91 Stockholm, Sweden
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENT
REFERENCES
ABSTRACT
The relationship between cAMP levels and
thermogenesis was investigated in brown fat cells from Syrian hamsters.
Irrespective of whether the selective 3-,
2-, and 1-agonists BRL 37344, salbutamol,
and dobutamine or the physiological agonist norepinephrine was used to
stimulate the cells, increases in cAMP levels were mediated via the
3-receptor, as were the thermogenic effects. However,
the relationship "thermogenesis per cAMP" was much lower for agents
other than norepinephrine. Similarly, forskolin, although more potent
than norepinephrine in elevating cAMP, was less potent in inducing
thermogenesis. The selective 1-agonist cirazoline was in
itself without effect on cAMP levels or thermogenesis, but when added
to forskolin-stimulated cells, potentiated thermogenesis, up to the
norepinephrine level, without affecting cAMP. This potentiation could
not be inhibited by chelerythrine, but could be mimicked by
Ca2+ ionophores. It was apparently not mediated via
calmodulin-dependent protein kinase and was not an effect
on mitochondrial respiratory control. The ability of all cAMP-elevating
agents to induce thermogenesis in brown fat cells has earlier been
interpreted to mean that it is only through the -receptors and the
resulting increase in cAMP levels that thermogenesis is induced.
However, it is here concluded that the thermogenic response to
norepinephrine involves two interacting parts, one mediated via
-receptors and cAMP and the other via 1-receptors and
increases in cytosolic Ca2+ levels.
INTRODUCTION
It is the generally accepted view (1-7) that the initial steps in
the pathway leading from norepinephrine stimulation of brown fat cells
to the final thermogenic reaction are quite well understood: through
interaction with -adrenergic receptors and transduction via
Gs proteins, norepinephrine activates adenylyl cyclase. The
sympathetic stimulation is thus intracellularly mediated by an increase
in cAMP levels. cAMP, through its activation of protein kinase A and a
subsequent activation of hormone-sensitive lipase, leads to release of
free fatty acids from the triglycerides in the cells. The free fatty
acids are combusted in the mitochondria; they are thus the substrate
for thermogenesis, and they are also, in a less well understood way,
involved in the activation of the uncoupling protein UCP1 (see for
example, Ref. 8 for review).
It is an inherent implication of this model that it is the cAMP level
in the brown fat cells that, during acute thermogenesis, solely
determines the final outcome of the acute sympathetic stimulation. Thus, the means by which the cAMP is elevated is implicitly not of
interest: any agent that has the ability to increase cAMP levels is
also expected to elicit a proportionate increase in thermogenesis.
However, this view has been so generally accepted that no detailed
analysis has been presented. We present here data challenging this
simple relationship and indicating that both a
3-receptor-induced increase in cAMP and an increase in
Ca2+ caused by 1-adrenergic stimulation may
in reality be of significance for the norepinephrine-induced
thermogenic process.
The presence of 1-adrenergic receptors in brown adipose
tissue has long been demonstrated (9-11), but until now, the role of
1-receptors in the acute thermogenic function of the
tissue has been considered to be small (12, 13) or nonexistent (14). We
have thus here unveiled a hitherto overlooked role of
1-adrenergic stimulation and confer to the
1-receptors on brown fat cells a significant role also
in the acute thermogenic process.
EXPERIMENTAL PROCEDURES
Isolation of Brown Adipocytes
Brown adipocytes were
isolated with the collagenase method described earlier (15). Each
preparation was from two adult (10-30-week old) Syrian hamsters
(Mesocricetus auratus) of either sex. The hamsters had been
kept at 20 ± 1 °C, one per cage, with food and water ad
libitum.
cAMP and Respiratory Rate Determinations
For parallel
measurements of cAMP levels and thermogenesis (rate of oxygen
consumption), 50,000-80,000 brown fat cells were added to a
magnetically stirred oxygen electrode chamber (thermostated at
37 °C) containing 1.1 ml of Krebs-Ringer bicarbonate buffer (see
"Buffers") and fitted with a Yellow Springs Model 4004 Clark-type oxygen probe. The suspension was covered with a lid, and the oxygen tension and oxygen consumption rate were continuously monitored. After
4 min, the agent was added with a syringe through a hole in the lid,
and the oxygen consumption was followed. After 10 min, the incubation
was terminated by taking a 0.5-ml aliquot of the suspension and
transferring it to 1 ml of 99.5% ethanol. This suspension was dried in
a Speedvac centrifuge for 12 h at room temperature. The dried
samples were dissolved in 200 µl of buffer 1 provided with the
[3H]cAMP assay system from Amersham Corp. and centrifuged
in an Eppendorf centrifuge at 12,000 rpm for 12 min. Two 50-µl
aliquots of the supernatants were analyzed according to the description provided with the assay system.
In certain experiments, only oxygen consumption was followed in the
same experimental system. In certain experiments, only cAMP levels were
followed in the same experimental system, but without the lid. For the
time course experiments, a similar setup was used, but a chamber
containing 4 ml of buffer was used, and successive sampling was
performed.
Buffers
Krebs-Ringer phosphate buffer (used only for cell
preparation and storage) had the following composition: 148 mM Na+, 6.9 mM K+, 1.5 mM Ca2+, 1.4 mM Mg2+,
119 mM Cl , 1.4 mM
SO42 , 5.6 mM
H2PO4 , 16.7 mM
HPO42 , 10 mM glucose, and
10 mM fructose. 4% crude bovine serum albumin was also
included. The pH was adjusted with Tris-OH or Tris-HCl to 7.4.
Krebs-Ringer bicarbonate buffer (used for all experiments) had the
following composition: 145 mM Na+, 6.0 mM K+, 2.5 mM Ca2+, 1.2 mM Mg2+, 128 mM Cl ,
1.2 mM SO42 , 25.3 mM HCO3 , 1.2 mM H2PO4 , 10 mM glucose, 10 mM fructose, and 2% fatty
acid-free bovine serum albumin. This buffer was purchased as a sterile
solution from Statens Veterinärmedicinska Anstalt (Uppsala,
Sweden). The buffer was bubbled with 5% CO2 in air, and
the pH was adjusted with Tris-OH or Tris-HCl to 7.4; the buffer was
continuously bubbled with a small stream of 5% CO2 in air
until use.
Chemicals
Crude bovine serum albumin and fatty acid-free
bovine serum albumin (albumin fraction V) were from Boehringer
Mannheim. L-Norepinephrine bitartrate (Arterenol),
forskolin, DL-propranolol, prazosin, yohimbine, A23187,
ionomycin, chelerythrine, EGTA, and crude collagenase (type II;
clostridiopeptidase A, EC 3.4.24.3) were obtained from Sigma (as the
DL-form of propranolol was used, pA2
values for L-propranolol are probably 0.3 units higher than
the values given below). BRL 37344 was a gift from SmithKline Beecham
Pharmaceuticals. Dobutamine (Dobutrex) was obtained as a solution for
infusion from Lilly (Fegersheim, France). Salbutamol (Ventoline) was
obtained as a solution for inhalation from Glaxo (Middlesex, UK).
Cirazoline, KN-92, and KN-93 were obtained from Research Biochemicals
International (Natick, MA). All adrenergic agents were freshly
dissolved in water, except prazosin, which was dissolved in ethanol and
diluted 1:10 in water for use. Forskolin and chelerythrine were
dissolved and diluted in Me2SO. A23187, KN-92, and KN-93
were dissolved in Me2SO and diluted in water for use. EGTA
was initially dissolved in dilute HCl.
Data Analysis
Dose-response curve data were, if not
otherwise indicated, analyzed with the general fit option of the
KaleidaGraph application for Macintosh for adherence to simple
Michaelis-Menten kinetics, i.e. V(x) = basal + Vmax·(x/(EC50 + x)). The indicated uncertainties are those obtained from the
fitting procedures. Where indicated, Michaelis-Menten kinetics with a
free Hill coefficient were used for fitting, i.e.
V(x) = Vmax·(xH/(EC50H + xH)), where H indicates the Hill
coefficient.
When estimated from single-dose antagonist curve shifts,
pA2 values were calculated as
pA2 = log(CR 1) log[antagonist], where CR is the ratio between the EC50 values in
the presence and absence of antagonist. For multiple-dose antagonist curve shifts, Schild plots were used as illustrated.
RESULTS
cAMP Accumulation
To investigate the relationship between
cAMP accumulation and thermogenesis in hamster brown fat cells, it was
first necessary to establish the time course for adrenergically induced
increases in cAMP levels.
In Fig. 1A, a time curve is
shown for the norepinephrine-induced increase in cAMP content in
suspensions of isolated brown fat cells. This experiment, as all
following, was performed in the absence of any phosphodiesterase
inhibitor; thus, it is the endogenously attained level of cAMP that is
followed, rather than adenylyl cyclase activation as such, and the
response includes the resultant hormonal effects, irrespective of
whether they affect cAMP production or degradation.
Fig. 1.
cAMP accumulation in isolated brown fat
cells. A, time course. The cells were incubated as described
under "Experimental Procedures," with successive sampling from one
chamber for each agent. At time 0, 1 µM BRL 37344, 1 µM norepinephrine (NE), or water (control
(Cont)) was added, and samples were drawn at the indicated
times. The points are means + S.E. from four independent cell
preparations, normalized to norepinephrine at 10 min (the mean level
was 34 ± 5 amol/cell). Here and in the following figures, the
absence of S.E. indications signifies that they were smaller than the
size of the symbol. B, dose-response curves for cAMP accumulation. Isolated brown adipocytes were incubated as described under "Experimental Procedures," with single incubations per point. The indicated concentrations of BRL 37344 or norepinephrine were added,
and the incubations were terminated at 10 min after addition of agent.
W indicates addition of solvent (water), followed by a
10-min incubation. The points are means + S.E. from five
independent cell preparations, normalized to 1 µM
norepinephrine. The mean level at 1 µM norepinephrine was
28 ± 3 amol/cell. Curves were drawn as detailed under
"Experimental Procedures" for the best fit to simple
Michaelis-Menten kinetics. The resulting values were, for
norepinephrine, a basal value of 0.15 ± 0.04, a maximal increase
of 1.50 ± 0.08, and an EC50 of 838 ± 219 nM (r = 0.99); for BRL 37344, the values
were 0.26 ± 0.05, 1.36 ± 0.07, and 26 ± 7 nM, respectively (r = 0.99).
[View Larger Version of this Image (17K GIF file)]
As seen, the initial increase was rapid, and the elevated cAMP levels
were maintained for at least 20 min. There was thus no tendency to the
transient "overshoot" behavior earlier observed in brown fat cell
preparations incubated under somewhat different conditions (16, 17),
and the cAMP levels were at least as well maintained as the
norepinephrine-induced thermogenesis (18).
Thermogenesis in these cells has been demonstrated to be mediated via
3-receptors (15), and we therefore also investigated the
cAMP response to a 3-agonist, BRL 37344. This response
had somewhat different kinetics than that to norepinephrine, and it did
not reach the maximum before 10 min. At any time point, the level
induced was slightly higher than that observed after norepinephrine. In
all subsequent experiments, cAMP was determined 10 min after addition
of agent.
Dose-response curves for the action of norepinephrine and BRL 37344 on
cAMP levels are shown in Fig. 1B. High concentrations of
norepinephrine were necessary to obtain a full effect on cAMP levels;
the EC50 for norepinephrine for elevation of cAMP was 840 nM. This value should be contrasted with that
associated with other effects of norepinephrine in these cells, such as
thermogenesis ( 200 nM (e.g. Ref. 15 and see
below).
In agreement with the results in the time course experiment, 1 µM BRL 37344 induced a higher level of cAMP than did 1 µM norepinephrine, although the maximal level attained by
BRL 37344 was not different from that of norepinephrine. The
EC50 was much lower than that for norepinephrine: 26 nM. Thus, as an elevator of cAMP levels in brown fat cells,
BRL 37344 was 30-fold more potent than norepinephrine.
That the elevation of cAMP levels was more efficiently induced by BRL
37344 than by norepinephrine may in itself be seen as an indication
that it is via stimulation of the 3-adrenergic receptors
that cAMP levels are increased. However, this does not unequivocally
demonstrate that the stimulation occurs through 3-receptors. Therefore, to establish through which
-receptor norepinephrine (and BRL 37344) elevates cAMP levels in
brown fat cells, we utilized the characteristic of
3-adrenergic receptors that they are relatively
insensitive to conventional -adrenergic antagonists, such as
propranolol. For interaction of propranolol with 1- or
2-receptors, the pA2 values
should be 8-9, but with 3-receptors, only 6 (19,
20). Therefore, dose-response curves for elevation of cAMP levels were
constructed in the absence and presence of a fixed dose of propranolol.
In Fig. 2A, it is shown that 8 µM propranolol was sufficient to induce a significant
shift of the dose-response curve for BRL 37344 to the right. The
pA2 for propranolol on BRL 37344-induced cAMP
elevation was only 5.9, indicating that, as expected, BRL 37344 increased cAMP by interaction with 3-receptors. When the
effect of propranolol on norepinephrine was investigated, the
pA2 was also 5.9, implying that the
physiological agonist norepinephrine also elevated cAMP levels through
interaction with 3-receptors.
Fig. 2.
Effect of the -adrenergic antagonist
propranolol on the dose-response curves for cAMP formation for
different agonists. A, effect on BRL 37344 and
norepinephrine (NE) dose-response curves. Dose-response
experiments were carried out principally as described for Fig.
1B, with parallel incubations containing 8 µM
propranolol (closed symbols) or not (open
symbols). The points are means + S.E. from two independent
cell preparations, normalized to 1 µM norepinephrine.
Dose-response curves for the results in the absence of propranolol were
drawn as detailed under "Experimental Procedures" (yielding basal,
maximal, and EC50 values), and the data in the presence of
propranolol were then evaluated with the same fitting procedure, but
with the EC50 as the only free parameter. The apparent
EC50 values for norepinephrine in the absence and presence
of propranolol were 489 and 3759 nM, respectively,
i.e. a CR of 7.7 and a pA2
for propranolol of 5.9. For BRL 37344, the values were 18 and 146 nM, respectively, with a CR of 8.1 and a
pA2 for propranolol also of 5.9. B,
effect on dobutamine (dobu) and salbutamol (salb)
dose-response curves. Experiments and analysis were performed as
described for A. The points are means + S.E. from three
independent cell preparations. For dobutamine, the EC50
values in the absence and presence of propranolol were 16 and 542 µM, respectively, i.e. a CR of 34 and
a pA2 for propranolol of 6.6. For salbutamol,
the values were 15 and 810 µM, respectively, with a
CR of 53 and a pA2 for propranolol of
6.8.
[View Larger Version of this Image (20K GIF file)]
Effect of Selective 1- and
2-Agonists
The above interpretation of the
response to norepinephrine being mediated through
3-receptors is based on the global response of the cells
to norepinephrine (as if only one -receptor type should be
involved). It could not be excluded that a minor elevation was induced
through other -receptors. To increase the possibility of observing
the activity of other -adrenergic receptors, adrenergic agents that
are selective for 1- or 2-receptors (here
dobutamine and salbutamol) were tested.
In the dose-response curve for dobutamine (Fig. 2B), there
was no measurable increase in cAMP at the low concentrations expected if dobutamine interacted with 1-receptors. No
significant elevation of cAMP content was observed at agonist
concentrations below 10 µM, and the EC50 was
as high as 16 µM. In the presence of 8 µM propranolol, only a marginal increase was observed at the highest dobutamine concentration, but this was still sufficient to estimate a
pA2 of 6.6. Thus, this selective
1-agonist did not display a high potency for increasing
cAMP levels (or even an observable component with a high potency), and
the observable action was probably through interaction with the
3-receptors. Thus, although 1-receptors
are found on these cells (21), we found no evidence for them being
coupled to increased cAMP levels.
Very similar results were obtained with the selective
2-agonist salbutamol (Fig. 2B). However, the
absence of specific 2-receptor interaction was less
unexpected, as no evidence has been presented for the presence of
2-receptors on these cells. It would therefore appear
that in these isolated mature brown adipocytes, cAMP elevation is
mediated only through 3-adrenergic receptors.
Stimulation of Thermogenesis
All agents tested above increase
cAMP and are therefore predicted to stimulate thermogenesis. This was
naturally the case for norepinephrine and BRL 37344 (Fig.
3A), as amply observed earlier. In the present investigation, the EC50 for
norepinephrine was 195 nM, and that for BRL 37344 was 24 nM. Thus, for thermogenesis, there was the same qualitative
difference between the agents as for cAMP elevation: BRL 37344 was more
potent than norepinephrine. There was, however, a remarkable
quantitative difference: although BRL 37344 was 30-fold more potent
than norepinephrine as an elevator of cAMP levels, it was only 8-fold
more potent as a stimulator of thermogenesis. This in itself implied
that the relationship between cAMP elevation and stimulation of
thermogenesis was not simple. The stimulation of thermogenesis by
norepinephrine and BRL 37344 has earlier been shown to have a
pA2 for propranolol of 6 (15), indicating
that both these agents are coupled through 3-receptors
(see also below).
Fig. 3.
Dose-response curves for stimulation of
oxygen consumption by -adrenergic agonists. Isolated brown
adipocytes were incubated for determination of oxygen consumption as
described under "Experimental Procedures." A,
norepinephrine (NE) and BRL 37344. The indicated
concentrations of the agents were added as a single addition
(cf. Fig. 7, first trace), and the maximal
respiration induced was then measured. The points are means + S.E.
from four independent cell preparations; the results were normalized to the respiration obtained at 1 µM norepinephrine in each
preparation (mean value of 667 ± 48 fmol O/min/cell). The
EC50 for norepinephrine was 195 ± 26 nM,
and that for BRL 37344 was 24 ± 11 nM. B,
norepinephrine, dobutamine (dobu), and salbutamol
(salb). The indicated concentrations of the agents were
added as successive additions, and the stable level of respiration
after each addition was measured. The points are means + or S.E. from four independent cell preparations; the results were
normalized to the respiration obtained at 1 µM norepinephrine in each preparation (mean value of 706 ± 97 fmol O/min/cell). The EC50 values were 219 ± 134 nM for norepinephrine, 9936 ± 1391 nM for
dobutamine, and 36,858 ± 7594 nM for salbutamol.
[View Larger Version of this Image (15K GIF file)]
It is to be expected that the increase in cAMP brought about by the
selective 1-agonist dobutamine or the selective
2-agonist salbutamol would also lead to thermogenesis,
but this has not earlier been demonstrated. In Fig. 3B, it
is shown that these agents could also induce a full thermogenic
response. To examine whether this response was mediated via a selective
interaction of these agents with their intended receptors
( 1 or 2) or unspecifically through
3-receptors, dose-response curves for thermogenesis were obtained for these agents (and, for comparison, for norepinephrine) in
the presence of three different propranolol concentrations. From these
curves (Fig. 4, A-C), Schild
plots were constructed, and apparent pA2 values
for propranolol were calculated (Fig. 4D). The
pA2 values were all between 5 and 6. Therefore,
although the brown fat cells respond thermogenically to selective
1- and 2-agonists, it is clear that these
agents mediated their effects through interaction with the
3-receptors.
Fig. 4.
Effect of propranolol on dose-response curves
for norepinephrine, salbutamol, and dobutamine stimulation of oxygen
consumption. A-C, experiments were performed principally as
described for Fig. 3B, but in the presence of the indicated
propranolol (Pro) concentrations. The points are means + S.E. from four independent cell preparations, with each agonist
tested in each cell preparation. H/P indicates the rate
after addition of water or propranolol. Data were analyzed as described
for Fig. 2A, and the resulting CR ratios were used
for construction of D. D, shown is a Schild plot
of propranolol inhibition of agonist-induced respiration. The lines are
drawn based on the best linear fit. The resulting pA2 values for propranolol were 5.6 against
dobutamine (dobu; slope of 0.9), 5.3 against norepinephrine
(NE; slope of 0.9), and 4.9 against salbutamol
(salb; slope of 1.5). Also indicated is the expected
pA2 value for propranolol interaction with
1- or 2-receptors.
[View Larger Version of this Image (29K GIF file)]
Relation between cAMP and Thermogenesis
Since cAMP production
and oxygen consumption were thus demonstrated (above) to be
3-receptor mediated processes, irrespective of which
adrenergic agent was used, the prediction would be that, irrespective
of which adrenergic agent is used, cAMP should be equally effective as
a thermogenic stimulator.
In Fig. 5A, the rate of oxygen
consumption (thermogenesis) stimulated by norepinephrine is plotted
against the cAMP increase induced by norepinephrine; this is thus the
dose-response curve for cAMP as a stimulator of thermogenesis. As
expected, increases in cAMP levels correlated with increases in oxygen
consumption until oxygen consumption peaked at the maximum capacity of
the cells for thermogenesis. As can be understood from the graphs above
and shown in Fig. 5A, higher norepinephrine concentrations could further increase the cAMP levels, but this was not associated with a further increase in thermogenesis.
Fig. 5.
Correlation between induced cAMP levels and
stimulation of oxygen consumption for different adrenergic agents.
A, correlation for norepinephrine (NE) and BRL
37344. The curves are based on the data in Figs. 1B and
3A. The curves were drawn as the best fit to
Michaelis-Menten kinetics with a free Hill coefficient, as detailed
under "Experimental Procedures." The apparent relative half-maximal
value for cAMP as a stimulator of thermogenesis when the cells had been
stimulated with norepinephrine was 0.43, and that when they had been
stimulated with BRL 37344 was 0.99. B, correlation for
norepinephrine, dobutamine, and salbutamol. The curves are based on the
data in Figs. 2B and 3B. The curves were drawn as
described for A. Here, the apparent relative half-maximal value with norepinephrine was 0.68, that with dobutamine
(dobu) was 0.86, and that with salbutamol (salb)
(read off the curve) was 1.2.
[View Larger Version of this Image (17K GIF file)]
Principally, a similar correlation was seen for the BRL
37344-stimulated increases in oxygen consumption and cAMP (Fig.
5A). However, there was an unexpected and important
distinction: the relationships between cAMP levels and thermogenesis
rates were not superimposable for the data sets for norepinephrine and
BRL 37344. For any nonsaturating level of cAMP generated by BRL 37344 stimulation, the resulting thermogenesis was lower than that obtained with cAMP generated by norepinephrine stimulation. Only when cAMP levels were markedly increased by BRL 37344 was a full thermogenic response reached. Therefore, the view that there is a simple
relationship between cAMP and thermogenesis is clearly not an adequate
description of the situation.
A similar set of curves (Fig. 5B) was generated for
dobutamine and salbutamol and compared with the norepinephrine response from the same series. It is again evident that the curves were not
superimposable: cAMP generated by stimulation with the selective pharmacological ligands was apparently less thermogenically potent than
that derived from norepinephrine stimulation. These differences in
apparent cAMP potency are even more unanticipated when it is remembered
that the increase in cAMP levels in all cases (both with norepinephrine
and with the three selective adrenergic agents) is mediated through the
same receptor, the 3-receptor (as demonstrated above).
Apparent Thermogenic Potency of cAMP of Non- -receptor
Origin
The difference between the potency of cAMP to stimulate
thermogenesis when it originates from norepinephrine stimulation of the
cells and when it originates from stimulation with the selective adrenergic agents could be due to a negative effect on thermogenesis of
the selective agents or to a positive effect of norepinephrine as
compared with the selective agents. To distinguish between these
possibilities, it was necessary to increase cAMP levels in a
non-adrenergic receptor-mediated way. Therefore, we investigated the
thermogenic potency of cAMP generated by stimulation with forskolin,
which directly stimulates adenylyl cyclase.
In Fig. 6A, dose-response
curves for the action of forskolin on the level of cAMP, compared with
norepinephrine, are presented. It is evident (and in agreement with
Ref. 22) that forskolin was able to massively stimulate cAMP
production, far in excess of the levels generated by norepinephrine.
However, when the effect of forskolin as a stimulator of thermogenesis
was investigated (Fig. 6B), a remarkable reversal was
observed: although forskolin was able to stimulate thermogenesis,
norepinephrine was more potent. Forskolin was not even able to fully
reach the level of norepinephrine-induced thermogenesis.
Fig. 6.
Dose-response curves for cAMP formation and
thermogenesis induced by forskolin and norepinephrine. A,
cAMP determinations. Experiments were performed as described for Fig.
1B, with the indicated concentrations of agents. The points
are means + S.E. from five independent cell preparations. The
curves were drawn with a free Hill coefficient, as detailed under
"Experimental Procedures." The EC50 for norepinephrine
(NE) was 5223 ± 1237 nM, and that for
forskolin (forsk) was 7364 ± 453 nM.
B, oxygen consumption. Experiments were performed as
described for Fig. 3A. The points are means + S.E. from
six independent cell preparations. The curves were drawn with a Hill
coefficient of 1. The EC50 for norepinephrine was 354 ± 150 nM, and that for forskolin was 4753 ± 1265 nM. C, correlation between induced cAMP levels
and stimulation of oxygen consumption. The curves are based on the data
in A and B and were drawn as described for Fig.
5A. The apparent relative half-maximal value for cAMP as a
stimulator of thermogenesis when the cells had been stimulated with
norepinephrine was 0.47, and that when they had been stimulated with
forskolin was 2.98.
[View Larger Version of this Image (15K GIF file)]
Curves were therefore again constructed to analyze the relationship
between cAMP levels and oxygen consumption. As is clear from Fig.
6C, a similar, but even more dramatic difference was seen
between norepinephrine and forskolin as between norepinephrine and the
selective agents (Fig. 5). The thermogenic potency of forskolin-generated cAMP was apparently markedly lower than that generated by norepinephrine. Thus, the higher thermogenic potency of
cAMP generated by norepinephrine stimulation compared with that
generated by the selective adrenergic agents (Fig. 5) was likely due to
an additional positive effect of norepinephrine.
An 1-Adrenergic Potentiating Effect
There is,
of course, an important difference between norepinephrine and the other
agents studied here: norepinephrine interacts with adrenergic receptor
subtypes other than , i.e. 2- and
1-adrenoreceptors. Concerning possible
2-adrenergic effects, it has earlier been demonstrated
that hamster brown fat cells apparently lack
2-adrenergic receptors (23), and this pathway is
therefore probably not relevant.
However, isolated brown fat cells have a high density of
1-adrenergic receptors (9) coupled to activation of
phosphatidylinositol bisphosphate turnover (24), protein kinase C
activation (25), inositol 1,4,5-trisphosphate production (26), and an
increase in cytosolic Ca2+ (27). In the present
circumstances, the possibility therefore existed that it could be
through interaction with 1-receptors that norepinephrine
potentiated the thermogenic effect of the -adrenergically generated
cAMP. Studies were therefore performed to investigate whether selective
1-adrenergic stimulation could potentiate the
thermogenic response to a given cAMP level. To avoid possible problems
with receptor specificity for selective adrenergic agents, we performed
these studies in cells in which the cAMP level was elevated with
forskolin. A dose of forskolin was chosen that (according to the data
in Fig. 6A) gave an increase in cAMP approximately similar
to that induced by the dose of norepinephrine that gave maximal oxygen
consumption.
First, we investigated the effect of 1-adrenergic
stimulation on thermogenesis. Results from a typical experiment are
seen in Fig. 7. Forskolin, at the dose
utilized, stimulated oxygen consumption to some 60% of the level
stimulated maximally by norepinephrine. Cirazoline, a selective
1-adrenergic receptor agonist, was in itself unable to
stimulate oxygen consumption at the concentration utilized here (and
indeed at any concentration between 1 nM and 10 µM) (data not shown here, but compare with Fig.
9A). However, when the cells were stimulated with cirazoline
in combination with forskolin, the forskolin-stimulated respiration
markedly increased, irrespective of whether cirazoline was added
together with or (as shown here) after forskolin.
Fig. 7.
Interaction between forskolin and cirazoline
in stimulation of oxygen consumption in isolated brown adipocytes.
Cell suspensions were incubated and rates of oxygen consumption were determined as described under "Experimental Procedures." Shown is a
representative experiment from one cell preparation. Additions were 1 µM norepinephrine (NE), 1 µM
cirazoline (Cir), and 3 µM forskolin
(Forsk).
[View Larger Version of this Image (9K GIF file)]
In Fig. 8A, a dose-response
curve is shown for this cirazoline-mediated potentiation of
forskolin-induced thermogenesis. The response was
dose-dependent, with an EC50 of 23 nM, i.e. within the order of affinity expected
for a cirazoline effect on 1-receptors. To confirm that
the cirazoline-induced potentiation was indeed mediated via
1-adrenergic receptors, the effects of antagonists to
1- and 2-receptors on the potentiation
were studied (Fig. 8B). The selective
2-antagonist yohimbine was without significant effect,
whereas the selective 1-antagonist prazosin completely blocked the cirazoline-mediated effect. Thus, provided that an increase
in cAMP had been induced by forskolin, 1-adrenergic stimulation was able to nearly double the thermogenic effect of this
amount of cAMP.
Fig. 8.
Cirazoline potentiation of forskolin-induced
thermogenesis. A, dose-response curve for cirazoline-induced
potentiation. Experiments were performed principally as described for
Fig. 7 (fourth trace), but forskolin and cirazoline were
added simultaneously. The cirazoline-induced increase ( oxygen
consumption) was determined as the oxygen consumption rate in traces
obtained with different cirazoline concentrations minus the rate when
only forskolin was added. The points are means + S.E. from four
experiments on the same number of independent cell preparations. The
EC50 for cirazoline was 23 ± 20 nM.
B, influence of -adrenergic antagonists on
cirazoline-induced potentiation. Experiments were performed principally
as described for Fig. 7 (fourth trace), except that
different concentrations of prazosin (pra) or yohimbine
(yoh) (or ethanol/water vehicle) were added 2.5 min prior to
addition of forskolin, and cirazoline and forskolin were added
simultaneously. The calculations were done as described for
A. The points are means ± S.E. from three independent
cell preparations.
[View Larger Version of this Image (15K GIF file)]
To eliminate the possibility that the increase in thermogenesis caused
by 1-adrenergic stimulation was due to an unexpected effect of cirazoline on cAMP accumulation, cAMP levels and
thermogenesis were determined in parallel in the presence of forskolin
and with varying cirazoline concentrations. The relationship between
cAMP levels and oxygen consumption is plotted in Fig.
9A.
Fig. 9.
Effect of cirazoline and calcium on the
correlation between induced cAMP levels and stimulation of oxygen
consumption. A, effect of cirazoline. Experiments were
performed as described for Fig. 6. In each experimental series, the
response to 1 µM norepinephrine (NE) was
determined and used to normalize the results. The results of addition
of different concentrations of cirazoline (1, 10, 100 nM, 1 and 10 µM) are plotted as open symbols. The effect of 3 µM forskolin (F) alone is
indicated, and the results of adding forskolin plus the different
cirazoline concentrations are shown (closed diamonds; from
left to right, the diamonds represent the following cirazoline concentrations: 1 nM, 100 nM, 10 nM and 10 µM). The points
are means ± S.E. from four independent cell preparations in which
oxygen consumption and cAMP levels were determined in parallel.
B, effect of Ca2+ ionophores. Experiments were
performed as described for A, except that either ionomycin
at different concentrations (closed triangles; from the
lowest point: 0.1, 1, and 10 µM) was used instead of cirazoline or 10 µM A23187 (F + A23;
inverted closed triangle) was used. The points are
means ± S.E. from four independent cell preparations in which
oxygen consumption and cAMP levels were determined in parallel.
[View Larger Version of this Image (18K GIF file)]
It is shown (Fig. 9A, open symbols, lower
left corner) that cirazoline in itself increased neither
thermogenesis nor cAMP levels. The concentration of forskolin used here
(point F) gave a level of cAMP very close to that obtained
with 1 µM norepinephrine (point NE), but only
half the thermogenesis. The further presence of cirazoline
(closed diamonds) had no dose-dependent effect
on cAMP levels, but was maximally able to approximately double
thermogenesis. Thus, although unable in itself to stimulate oxygen
consumption and without any innate ability to elevate cAMP levels,
cirazoline dramatically potentiated the forskolin-stimulated
respiration.
Mediation of the 1-Adrenergic Effect
The
intracellular signal transduction of this 1-adrenergic
potentiation of the forskolin-stimulated respiration could be through
either of the two arms of the 1-receptor pathway,
i.e. either via an activation of protein kinase C or via an
increase in [Ca2+]i.
To investigate whether the effect was protein kinase C-mediated, the
cells were treated with various concentrations of the protein kinase C
inhibitor chelerythrine prior to stimulation with forskolin plus
cirazoline. As is evident in Table I,
chelerythrine had no effect on the (forskolin + cirazoline)-stimulated
respiration. It would thus appear that protein kinase C was not
involved in the signal transduction of this effect of cirazoline.
Table I.
Influence of the protein kinase C inhibitor chelerythrine on oxygen
consumption stimulated by forskolin plus cirazoline
The experiments were performed as exemplified in Fig. 7 (last
trace), except that forskolin and cirazoline were added
simultaneously and the indicated additions of chelerythrine were made 3 min before addition of forskolin + cirazoline. Values are
means ± S.E. from three experiments, performed on independent
cell preparations.
|
|
Basal |
+Forskolin
|
|
| H2O |
98
± 17 |
435 ± 51 |
| Cirazoline |
105 ± 35 |
585 ± 26
|
| +0.1 µM chelerythrine |
99 ± 21 |
593
± 61 |
| +1 µM chelerythrine |
102 ± 13 |
586
± 43 |
| +10 µM chelerythrine |
86 ± 18 |
643
± 8 |
|
It was therefore likely that the cirazoline effect was mediated by an
increase in cytosolic calcium levels. If this was the case, the effect
of cirazoline should be mimicked by Ca2+ ionophores.
Therefore, an experiment similar to that in Fig. 9A was
performed, but various concentrations of the calcium ionophore ionomycin were used instead of cirazoline. The results are shown in
Fig. 9B. Ionomycin in itself affected neither cAMP levels
nor thermogenesis (open symbols, lower left
corner). However, when ionomycin was added to cells together with
forskolin, it was again possible to dose-dependently
increase thermogenesis from the forskolin level (point F) to
the level obtained with norepinephrine (point NE) without
any systematic effect on cAMP levels. A similar effect was seen with
the Ca2+ ionophore A23187 (point F + A23). Both
Ca2+ ionophores could thus mimic the effect of
1-adrenergic stimulation, indicating that an elevation
of intracellular calcium was a sufficient signal to potentiate
forskolin-induced respiration in a cAMP-independent manner.
The calcium causing the potentiation could originate from intracellular
stores or from an increased influx from the medium. We have earlier
found that even in the absence of extracellular Ca2+,
1-adrenergic stimulation can increase
[Ca2+]i in these cells (27), although to a
somewhat lower level than in its presence. To investigate the origin of
the Ca2+ required for the potentiating effect, we chelated
extracellular Ca2+ with EGTA prior to addition of forskolin
plus cirazoline. We observed no significant effect of EGTA on the
magnitude of the cirazoline potentiation of thermogenesis (158 ± 11 fmol O/cell/min in the absence of EGTA and 141 ± 33 in the
presence of 5 mM EGTA; means ± S.E. from four
independent experiments). It would thus appear that the calcium for the
potentiating effect could be derived from intracellular stores.
The effects of the 1-receptor-induced increase in
cytosolic calcium levels may be mediated through activation of
calmodulin-dependent protein kinase. To evaluate if this
kinase was a necessary step in the calcium-mediated cirazoline effect,
a 1 µM concentration of the
calmodulin-dependent protein kinase inhibitor KN-93 or the
inactive analogue KN-92 was added to the cells prior to forskolin + cirazoline. Neither agent influenced the magnitude of the cirazoline potentiation of thermogenesis (data not shown). Thus,
calmodulin-dependent protein kinase is probably not the
route by which the calcium activation of respiration is achieved.
The potentiation of thermogenesis caused by 1-adrenergic
stimulation could be localized to different steps between the increased cAMP levels and the final thermogenic result. It could be possible that
1-adrenergic stimulation in itself had an uncoupling
effect, allowing for thermogenesis provided that substrate was
otherwise available. The substrate would physiologically be provided by -receptor-stimulated lipolysis, but it is possible experimentally to
provide substrate by addition of pyruvate. Pyruvate (at a concentration of 5 mM) had virtually no effect on thermogenesis, but when
an artificial uncoupler
(FCCP,1 100 µM)
was added, a clear thermogenic response (~45% of that to
norepinephrine) was induced; such a response was not observed if no
pyruvate was present. If 1-adrenergic stimulation in
itself was able to uncouple, a response to cirazoline (in the presence of pyruvate) similar to that to FCCP would be expected, but cirazoline was practically without effect under these circumstances (data not
shown). Thus, 1-adrenergic stimulation probably had no
uncoupling effect in itself.
A further possibility would be that 1-adrenergic
stimulation would provide extra substrate for thermogenesis (in
addition to that provided by lipolysis). Thus, when the mitochondria
became uncoupled due to -adrenergic stimulation, both the substrate from lipolysis and that emanating from 1-adrenergic
stimulation would be combusted. We therefore tested whether the
thermogenic response to the uncoupler FCCP would be larger if the cells
were first stimulated with cirazoline; this was, however, not the case (data not shown). Thus, 1-adrenergic stimulation
probably did not provide additional thermogenic substrate.
It could also be suggested that 1-adrenergic
stimulation, e.g. through its effects on cytosolic
Ca2+ levels, could facilitate the combustion of thermogenic
substrate from -receptor-stimulated lipolysis. This could occur
through Ca2+-induced stimulation of enzymes of the citric
acid cycle (28) or through mitochondrial matrix expansion caused, for
example, by activation of the K+ channel (29); such matrix
expansion would facilitate thermogenesis (30). In an attempt to
investigate this, we examined if cirazoline would augment FCCP-induced
thermogenesis with pyruvate as substrate. However, this was not the
case (data not shown). Thus, at least under these experimental
conditions, 1-adrenergic stimulation did not facilitate
substrate combustion, but the situation may, of course, be different
under physiological conditions when flow through the citric acid cycle
is greater than that occurring with pyruvate as added substrate.
In studies parallel to those above, we examined if raising cytosolic
Ca2+ levels by the ionophore A23187 (100 nM to
10 µM) would induce the features discussed above. The
results with this Ca2+ ionophore were practically identical
to those obtained with cirazoline; thus, neither
1-adrenergic stimulation nor an increase in
[Ca2+]i was able to uncouple the mitochondria, to
provide additional substrate, or to facilitate substrate combustion
under the conditions tested. Thus, the potentiating effect of
1-adrenergic stimulation on the ability of cAMP to
induce thermogenesis is apparently located at a step between increased
cAMP levels and physiological uncoupling of the brown fat
mitochondria.
DISCUSSION
In this investigation, we first demonstrated that the
adrenergically mediated increase in cAMP levels in hamster brown fat cells is mediated via 3-receptors, irrespective of which
adrenergic agent is used. Despite this homogeneous mediation of cAMP
formation, we observed that cAMP derived from norepinephrine
stimulation was apparently more thermogenically potent than cAMP
generated from stimulation with selective adrenergic agonists or with
forskolin. We demonstrated that this difference was due to the
1-adrenergic component of norepinephrine stimulation,
which was without thermogenic effect itself but which augmented the
apparent thermogenic effect of cAMP. This 1-adrenergic
component was mediated via an increase in
[Ca2+]i. The 1-adrenergic effect
was not directly on the mitochondrial thermogenic process. The
observations confer to the 1-receptor pathway a
quantitatively significant role in the acute regulation of
thermogenesis.
Only 3-Receptors Are Involved in cAMP Elevation in
Hamster Brown Fat Cells
Our results ascribe the adrenergically
mediated increase in cAMP levels solely to stimulation of
3-receptors and give no indication of a
1-receptor involvement in this process. This was seen
both by the high sensitivity of cAMP formation to activation by the
selective 3-agonist BRL 37344 and by the low sensitivity to activation by the selective 1-agonist dobutamine and
the selective 2-agonist salbutamol. It was also clear
from the interaction of the -antagonist propranolol with these
agents that the pA2 values obtained in all four
cases clearly indicated interaction with 3-receptors,
and the monophasic curves obtained did not indicate interaction with
multiple receptors.
The results obtained here for brown fat cells from Syrian hamsters
(that only 3-receptors are involved in the adrenergic elevation of cAMP levels) may not necessarily be valid for brown fat
cells from all species. The involvement of the different -receptor subtypes in stimulation of adipose tissues is apparently very species-specific, and also the pharmacology of the
3-receptor is apparently variable between species (7,
31). The clear-cut result obtained for the hamster cells facilitates,
however, interpretation of the relationship between cAMP elevation and
thermogenesis stimulation (below).
This result implies that the 1-receptors, earlier
characterized on these isolated hamster brown fat cells (21), are not coupled to classical mediation through cAMP, and they appear therefore not to be functional. This may be due to a decoupling occurring during
cellular differentiation; at least in mouse and rat brown preadipocytes
in culture, the 1-receptors are coupled (32-34) and
stimulate cell proliferation (32, 35, 36) (although the predominant
receptor after differentiation also in these cells is the
3-receptor (32)).
Relationship between Cellular cAMP Levels and
Thermogenesis
Since the formation of cAMP by all adrenergic
agonists occurred through the same receptor, it would be expected that
the resulting level of cAMP would correlate well with the stimulation
of thermogenesis. It was, however, evident that cAMP generated by
norepinephrine was more efficient in stimulating thermogenesis than
that generated by other -adrenergic agonists or by forskolin. We
analyzed this difference in apparent potency and demonstrated that it
was due to the simultaneous activation of 1-adrenergic
receptors by norepinephrine.
Another formulation of the difference in apparent thermogenic potency
of cAMP derived from norepinephrine stimulation and that derived from,
for example, forskolin stimulation could be that the cAMP in these
cells is functionally compartmentalized: some forskolin-derived cAMP
could be postulated to be in a compartment not coupled to
thermogenesis. In this formulation, 1-adrenergic stimulation may be said to direct the cAMP to a better coupled functional compartment.
A compartmentalization of cAMP has been discussed in other systems
(e.g. Ref. 37), often under conditions where, for example, forskolin-derived cAMP and cAMP derived from hormonal stimulation apparently do not induce the final cellular response with the same
potency, i.e. a situation akin to the one described here for
brown fat cells. Based on the results presented here, it may be
suggested that in some of these cases, a parallel hormonal stimulation
of, for example, an inositol
1,4,5-trisphosphate/[Ca2+]i pathway may also
convey to the cAMP a full effector capacity.
Why Has This Effect of 1-Adrenergic Stimulation Been
Overlooked?
It may seem surprising that such a quantitatively
significant effect of 1-adrenergic stimulation has
previously gone unnoticed in brown fat cells. However, direct
comparisons between cAMP levels and thermogenesis (as those shown here
in Figs. 5 and 6C) have only rarely been presented and only
with norepinephrine as the stimulatory agent (e.g. Ref. 38);
thus, no comparison between the relative efficiencies of different
agents has been made. Furthermore, the ability of cAMP-elevating agents
to stimulate thermogenesis to practically the same level as that
observed with norepinephrine has been taken as an indication that only
cAMP is involved in the signaling process. In reality, these
experiments only demonstrated that (high) cAMP can elicit
full thermogenesis, not that this is what actually occurs during
physiological stimulation. Also in the interpretation of the effect of
norepinephrine, it is clear that the exact experimental conditions
affect the interpretation. Thus, at a concentration of norepinephrine
that is supersaturating for thermogenesis, a sufficiently high level of
cAMP would be formed to fully induce thermogenesis, even if the
1-adrenergic component observed here were experimentally
inhibited. Thus, the erroneous conclusion would be that no
1-adrenergic component is involved in the adrenergic
effect. However, as seen here, at all concentrations of norepinephrine
at which the cells demonstrate a graded response to the agonist, the
1-adrenergic component is apparently of quantitatively
similar significance to the -adrenergic component, and this is
probably the physiologically most relevant condition.
There is also an interesting observation extending the significance of
the present results. Noronha et al. (39) found that in brown
fat cells isolated from normal rats, no evidence for an
1-adrenergic component in thermogenesis could be
discerned. However, in brown fat cells isolated from hypothyroid rats,
it was possible to observe an enhanced thermogenesis by
1-adrenergic stimulation. Based on the present
experiments, it may be postulated that in the cells from normal rats,
forskolin was able to increase cAMP to the unphysiologically high level
where it can alone elicit practically full thermogenesis
(cf. Fig. 6). However, in cells from hypothyroid rats,
forskolin had a diminished ability to elevate cAMP levels (40), and
only "physiological" cAMP levels were attained. Under these
circumstances, as demonstrated here, an 1-adrenergic
stimulation could confer full thermogenic potency to the cAMP, and
therefore, an 1-adrenergic effect became observable in
this pathological state, even when forskolin was used to stimulate adenylyl cyclase.
In this study and in Ref. 39, 1-adrenergic stimulation
in itself had no ability to stimulate thermogenesis; the effect was
only synergistic. This is apparently in contrast to earlier observations that selective 1-receptor activation in
itself stimulated a small amount of oxygen consumption (10-20% of
maximal norepinephrine) (12, 13, 41). However, considering the marked
ability of 1-adrenergic stimulation demonstrated here to
increase the thermogenic potency of small amounts of cAMP, it may be
suggested that it was such a potentiating effect that was seen, as the
actual conditions then used may have led to stimulation of cAMP
formation, the thermogenic effect of which was then augmented by the
1-adrenergic stimulation.
An Increasing Understanding of the Significance of
1-Adrenergic Receptors in Brown Adipose
Tissue
1-Adrenergic receptors were first
characterized in brown fat cells by radioligand binding studies with
prazosin (9). Many features of these receptors have subsequently been
described, including up- and down-regulation in relation to sympathetic
stimulation (10, 42-45) and coupling of 1-receptor
stimulation to activation of second messengers and ionic events in
brown fat cells (22, 24, 27, 46-52). However, the physiological role
of the 1-receptors has remained unclear, and reported
physiological effects of selective 1-adrenergic
stimulation have been minor, especially when compared with the fact
that the levels of 1-receptor mRNA in the tissue are
among the highest in the body (45).
This study may be seen as one in an emerging series in which evidence
is presented indicating that the importance of
1-adrenergic stimulation is its positive and often
synergistic interaction with -adrenergic responses. For regulation
of the expression of the uncoupling protein UCP1 (53, 54) and
lipoprotein lipase (55), an 1-adrenergic component has
been identified, and a synergistic interaction between
1- and -receptors and signaling pathways has
been demonstrated for both thyroxine deiodinase (40) and
c-fos (22) expression. Here, unexpectedly, we demonstrate that even for a process that has been accepted to be essentially -adrenergically stimulated and cAMP-mediated, a strong
1/ -receptor synergism can be observed.
Physiological stimulation with norepinephrine has broad effects on
brown adipose tissue (56). Many important processes in these cells have
been described to be positively controlled by cAMP, including
mitochondriogenesis in general (57), differentiation in general (58),
and, somewhat unusually, even brown fat cell proliferation (32, 36).
However, in few of these cases has a thorough analysis of the
significance of cAMP been made, and in the light of the present
observations, where an 1/ -receptor synergism is very
apparent in a process earlier believed to be essentially cAMP-mediated,
it may be suggested that some of the functions earlier claimed to be
-receptor/cAMP-mediated may be reanalyzed to unveil significant
1-adrenergic effects. Thus, the present demonstration of
the 1/ -receptor and [Ca2+]i
cAMP synergism in the acute thermogenic function of the tissue may also
be of significance for the understanding of the recruitment process
that augments the total thermogenic capacity of the tissue.
FOOTNOTES
*
This work was supported by a grant from the Swedish Natural
Science Research Council.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed. Tel.: 46-8-164128;
Fax: 46-8-156756; E-mail: jan{at}metabol.su.se.
1
The abbreviation used is: FCCP,
carbonyl cyanide p-trifluoromethoxyphenylhydrazone.
ACKNOWLEDGEMENT
We thank Gennady Bronnikov for advice on cAMP
determination.
REFERENCES
-
Smith, R. E., and Horwitz, B. A.
(1969)
Physiol. Rev.
49,
330-425
[Free Full Text]
-
Nedergaard, J., and Lindberg, O.
(1982)
Int. Rev. Cytol.
74,
187-286
[Medline]
[Order article via Infotrieve]
-
Nicholls, D. G., and Locke, R. M.
(1984)
Physiol. Rev.
64,
1-64
[Free Full Text]
-
Cannon, B., and Nedergaard, J.
(1985)
Essays Biochem.
20,
110-164
[Medline]
[Order article via Infotrieve]
-
Bukowiecki, L. J.
(1986)
in
Brown Adipose Tissue (Trayhurn, P., and Nicholls, D. G., eds), pp. 105-121, Edward Arnold, London
-
Himms-Hagen, J.
(1989)
Prog. Lipid Res.
28,
67-115
[CrossRef][Medline]
[Order article via Infotrieve]
-
Lafontan, M., and Berlan, M.
(1993)
J. Lipid Res.
34,
1057-1091
[Abstract]
-
Nedergaard, J., and Cannon, B.
(1992)
New Compr. Biochem.
23,
385-420
-
Mohell, N., Svartengren, J., and Cannon, B.
(1983)
Eur. J. Pharmacol.
92,
15-25
[CrossRef][Medline]
[Order article via Infotrieve]
-
Raasmaja, A., Mohell, N., and Nedergaard, J.
(1985)
Eur. J. Pharmacol.
106,
489-498
[CrossRef]
-
Costain, W. J., Mainra, R., Desautels, M., and Sulakhe, P. V.
(1996)
Can. J. Physiol. Pharmacol.
74,
234-240
[CrossRef][Medline]
[Order article via Infotrieve]
-
Mohell, N., Nedergaard, J., and Cannon, B.
(1983)
Eur. J. Pharmacol.
93,
183-193
[CrossRef][Medline]
[Order article via Infotrieve]
-
Schimmel, R. J., McCarthy, L., and McMahon, K. K.
(1983)
Am. J. Physiol.
244,
C362-C368
[Abstract/Free Full Text]
-
Bukowiecki, L., Follea, N., Paradis, A., and Collet, A.
(1980)
Am. J. Physiol.
238,
E552-E563
[Abstract/Free Full Text]
-
Zhao, J., Unelius, L., Bengtsson, T., Cannon, B., and Nedergaard, J.
(1994)
Am. J. Physiol.
267,
C969-C979
[Abstract/Free Full Text]
-
Pettersson, B., and Vallin, I.
(1976)
Eur. J. Biochem.
62,
383-390
[Medline]
[Order article via Infotrieve]
-
Pettersson, B.
(1977)
Eur. J. Biochem.
72,
235-240
[Medline]
[Order article via Infotrieve]
-
Nedergaard, J., and Lindberg, O.
(1979)
Eur. J. Biochem.
95,
139-145
[Medline]
[Order article via Infotrieve]
-
Arch, J. R. S.
(1989)
Proc. Nutr. Soc.
48,
215-223
[CrossRef][Medline]
[Order article via Infotrieve]
-
Arch, J. R. S., and Kaumann, A. J.
(1993)
Med. Res. Rev.
13,
663-729
[CrossRef][Medline]
[Order article via Infotrieve]
-
Svoboda, P., Svartengren, J., Snochowski, M., Houstek, J., and Cannon, B.
(1979)
Eur. J. Biochem.
102,
203-210
[Medline]
[Order article via Infotrieve]
-
Thonberg, H., Zhang, S.-J., Tvrdik, P., Jacobsson, A., and Nedergaard, J.
(1994)
J. Biol. Chem.
269,
33179-33186
[Abstract/Free Full Text]
-
McMahon, K. K., and Schimmel, R. J.
(1982)
Life Sci.
30,
1185-1192
[CrossRef][Medline]
[Order article via Infotrieve]
-
Mohell, N., Wallace, M., and Fain, J. N.
(1984)
Mol. Pharmacol.
25,
64-69
[Abstract]
-
Barge, R. M., Mills, I., Silva, E., and Larsen, P. R.
(1988)
Am. J. Physiol.
254,
E323-E327
[Abstract/Free Full Text]
-
Nånberg, E., and Nedergaard, J.
(1987)
Biochim. Biophys. Acta
930,
438-445
[Medline]
[Order article via Infotrieve]
-
Wilcke, M., and Nedergaard, J.
(1989)
Biochem. Biophys. Res. Commun.
163,
292-300
[CrossRef][Medline]
[Order article via Infotrieve]
-
McCormack, J. G., Halestrap, A. P., and Denton, R. M.
(1990)
Physiol. Rev.
70,
391-425
[Free Full Text]
-
Garlid, K. D.
(1996)
Biochim. Biophys. Acta
1275,
123-126
[Medline]
[Order article via Infotrieve]
-
Nicholls, D. G., Grav, H. J., and Lindberg, O.
(1972)
Eur. J. Biochem.
31,
526-533
[Medline]
[Order article via Infotrieve]
-
Lafontan, M.
(1994)
Cell. Signalling
6,
363-392
[CrossRef][Medline]
[Order article via Infotrieve]
-
Bronnikov, G., Houstek, J., and Nedergaard, J.
(1992)
J. Biol. Chem.
267,
2006-2013
[Abstract/Free Full Text]
-
Nisoli, E., Tonello, C., and Carruba, M. O.
(1995)
Arch. Int. Pharmacodyn.
329,
436-453
-
Rohlfs, E. M., Daniel, K. W., Premont, R. T., Kozak, L. P., and Collins, S.
(1995)
J. Biol. Chem.
270,
10723-10732
[Abstract/Free Full Text]
-
Nisoli, E., Tonello, C., Landi, M., and Carruba, M. O.
(1996)
Mol. Pharmacol.
49,
7-14
[Abstract]
-
Shimizu, Y., Tanishita, T., Minokoshi, Y., and Shimazu, T.
(1997)
Endocrinology
138,
248-253
[Abstract/Free Full Text]
-
Hollenga, C., Brouwer, F., and Zaagsma, J.
(1991)
Br. J. Pharmacol.
102,
577-580
[Medline]
[Order article via Infotrieve]
-
Unelius, L., Bronnikov, G., Mohell, N., and Nedergaard, J.
(1993)
Am. J. Physiol.
265,
C1340-C1348
[Abstract/Free Full Text]
-
Noronha, M., Raasmaja, A., Moolten, N., and Larsen, P. R.
(1991)
Metab. Clin. Exp.
40,
1327-1332
-
Raasmaja, A., and Larsen, P. R.
(1989)
Endocrinology
125,
2502-2509
[Abstract/Free Full Text]
-
Mohell, N., Connolly, E., and Nedergaard, J.
(1987)
Am. J. Physiol.
253,
C301-C308
[Abstract/Free Full Text]
-
Raasmaja, A., Mohell, N., and Nedergaard, J.
(1984)
Biosci. Rep.
4,
851-859
[CrossRef][Medline]
[Order article via Infotrieve]
-
Raasmaja, A., and York, A.
(1986)
Biochem. J.
249,
831-838
-
Granneman, J. G., Zhai, Y., and Lahners, K. N.
(1997)
Mol. Pharmacol.
51,
644-650
[Abstract/Free Full Text]
-
Kikuchi-Utsumi, K., Kikuchi-Utsumi, M., Cannon, B., and Nedergaard, J.
(1997)
Biochem. J.
322,
417-424
-
Horwitz, B. A., Horowitz, J. M., and Smith, R. E.
(1969)
Proc. Natl. Acad. Sci. U. S. A.
64,
113-120
[Abstract/Free Full Text]
-
Nånberg, E., and Putney, J. J.
(1986)
FEBS Lett.
195,
319-322
[CrossRef][Medline]
[Order article via Infotrieve]
-
Connolly, E., Nånberg, E., and Nedergaard, J.
(1984)
Eur. J. Biochem.
141,
187-193
[Medline]
[Order article via Infotrieve]
-
Nånberg, E., Nedergaard, J., and Cannon, B.
(1984)
Biochim. Biophys. Acta
804,
291-300
[Medline]
[Order article via Infotrieve]
-
Dasso, L., Connolly, E., and Nedergaard, J.
(1990)
FEBS Lett.
262,
25-28
[CrossRef][Medline]
[Order article via Infotrieve]
-
Lee, S. C., Nuccitelli, R., and Pappone, P. A.
(1993)
Am. J. Physiol.
264,
C217-C228
[Abstract/Free Full Text]
-
Pappone, P. A., and Lee, S. C.
(1995)
J. Gen. Physiol.
106,
231-258
[Abstract/Free Full Text]
-
Kopecky, J., Baudysová, M., Zanotti, F., Janíková, D., Pavelka, S., and Houstek, J.
(1990)
J. Biol. Chem.
265,
22204-22209
[Abstract/Free Full Text]
-
Rehnmark, S., Néchad, M., Herron, D., Cannon, B., and Nedergaard, J.
(1990)
J. Biol. Chem.
265,
16464-16471
[Abstract/Free Full Text]
-
Kuusela, P., Rehnmark, S., Jacobsson, A., Cannon, B., and Nedergaard, J.
(1997)
Biochem. J.
231,
759-767
-
Nedergaard, J., Herron, D., Jacobsson, A., Rehnmark, S., and Cannon, B.
(1995)
Int. J. Dev. Biol.
39,
827-837
[Medline]
[Order article via Infotrieve]
-
Néchad, M., Nedergaard, J., and Cannon, B.
(1987)
Am. J. Physiol.
253,
C889-C894
[Abstract/Free Full Text]
-
Herron, D., Néchad, M., Rehnmark, S., Nelson, B. D., Nedergaard, J., and Cannon, B.
(1989)
Am. J. Physiol.
257,
C920-C925
[Abstract/Free Full Text]
Volume 272, Number 52,
Issue of December 26, 1997
pp. 32847-32856
©1997 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
J. E. Sprague, X. Yang, J. Sommers, T. L. Gilman, and E. M. Mills
Roles of Norepinephrine, Free Fatty Acids, Thyroid Status, and Skeletal Muscle Uncoupling Protein 3 Expression in Sympathomimetic-Induced Thermogenesis
J. Pharmacol. Exp. Ther.,
January 1, 2007;
320(1):
274 - 280.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Li, G. Zhang, H. Holtby, T. Humpl, C. A. Caldarone, G. S. Van Arsdell, and A. N. Redington
Adverse Effects of Dopamine on Systemic Hemodynamic Status and Oxygen Transport in Neonates After the Norwood Procedure
J. Am. Coll. Cardiol.,
November 7, 2006;
48(9):
1859 - 1864.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. E. Rusyniak, S. L. Tandy, S. K. Hekmatyar, E. Mills, D. J. Smith, N. Bansal, D. MacLellan, M.-E. Harper, and J. E. Sprague
The Role of Mitochondrial Uncoupling in 3,4-Methylenedioxymethamphetamine-Mediated Skeletal Muscle Hyperthermia and Rhabdomyolysis
J. Pharmacol. Exp. Ther.,
May 1, 2005;
313(2):
629 - 639.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. CANNON and J. NEDERGAARD
Brown Adipose Tissue: Function and Physiological Significance
Physiol Rev,
January 1, 2004;
84(1):
277 - 359.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. A. Zaninovich, I. Rebagliati, M. Raices, C. Ricci, and K. Hagmuller
Mitochondrial respiration in muscle and liver from cold-acclimated hypothyroid rats
J Appl Physiol,
October 1, 2003;
95(4):
1584 - 1590.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Ravinet Trillou, M. Arnone, C. Delgorge, N. Gonalons, P. Keane, J.-P. Maffrand, and P. Soubrie
Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice
Am J Physiol Regulatory Integrative Comp Physiol,
February 1, 2003;
284(2):
R345 - R353.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Shabalina, C. Wiklund, T. Bengtsson, A. Jacobsson, B. Cannon, and J. Nedergaard
Uncoupling protein-1: involvement in a novel pathway for beta -adrenergic, cAMP-mediated intestinal relaxation
Am J Physiol Gastrointest Liver Physiol,
November 1, 2002;
283(5):
G1107 - G1116.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Koivisto, D. Siemen, and J. Nedergaard
Norepinephrine-induced sustained inward current in brown fat cells: alpha 1-mediated by nonselective cation channels
Am J Physiol Endocrinol Metab,
November 1, 2000;
279(5):
E963 - E977.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. E. Bronnikov, S.-J. Zhang, B. Cannon, and J. Nedergaard
A Dual Component Analysis Explains the Distinctive Kinetics of cAMP Accumulation in Brown Adipocytes
J. Biol. Chem.,
December 31, 1999;
274(53):
37770 - 37780.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Bronnikov, T. Bengtsson, L. Kramarova, V. Golozoubova, B. Cannon, and J. Nedergaard
{beta}1 to {beta}3 Switch in Control of Cyclic Adenosine Monophosphate during Brown Adipocyte Development Explains Distinct {beta}-Adrenoceptor Subtype Mediation of Proliferation and Differentiation
Endocrinology,
September 1, 1999;
140(9):
4185 - 4197.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
M. Desautels and S. Heal
Differentiation-dependent inhibition of proteolysis by norepinephrine in brown adipocytes
Am J Physiol Endocrinol Metab,
August 1, 1999;
277(2):
E215 - E222.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Zhao, B. Cannon, and J. Nedergaard
Thermogenesis is beta 3- but not beta 1-adrenergically mediated in rat brown fat cells, even after cold acclimation
Am J Physiol Regulatory Integrative Comp Physiol,
December 1, 1998;
275(6):
R2002 - R2011.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Matthias, K. B. E. Ohlson, J. M. Fredriksson, A. Jacobsson, J. Nedergaard, and B. Cannon
Thermogenic Responses in Brown Fat Cells Are Fully UCP1-dependent. UCP2 OR UCP3 DO NOT SUBSTITUTE FOR UCP1 IN ADRENERGICALLY OR FATTY ACID-INDUCED THERMOGENESIS
J. Biol. Chem.,
August 11, 2000;
275(33):
25073 - 25081.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. P. Commins, P. M. Watson, N. Levin, R. J. Beiler, and T. W. Gettys
Central Leptin Regulates the UCP1 and ob Genes in Brown and White Adipose Tissue via Different beta -Adrenoceptor Subtypes
J. Biol. Chem.,
October 13, 2000;
275(42):
33059 - 33067.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. M. Lindquist, J. M. Fredriksson, S. Rehnmark, B. Cannon, and J. Nedergaard
beta 3- and alpha 1-Adrenergic Erk1/2 Activation Is Src- but Not Gi-mediated in Brown Adipocytes
J. Biol. Chem.,
July 21, 2000;
275(30):
22670 - 22677.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. V. Leaver and P. A. Pappone
beta -Adrenergic potentiation of endoplasmic reticulum Ca2+ release in brown fat cells
Am J Physiol Cell Physiol,
May 1, 2002;
282(5):
C1016 - C1024.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 1997 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|